Oral cancer is becoming increasingly common and new risk factors have been recognised. Treatment remains largely surgical, but radiotherapy and, increasingly, chemotherapy and targeted therapy have roles to play.
The term 'head and neck cancer' covers a large number of neoplasms with diverse natural history, most of which are uncommon and some of which are rare. These lesions, in over 85% of cases, represent squamous cell carcinomas of the mucosa of the upper respiratory and gastrointestinal tracts -head and neck squamous cell carcinoma (HNSCC) -and most are oral squamous cell carcinoma (OSCC). This review discusses HNSCC but focuses largely on OSCC; it does not include lip cancer.
Epidemiology
HNSCC is the sixth most common cancer worldwide. It affects males twice as commonly as females and shows a peak age at presentation between the fifth and seventh decades of life. In the US, HNSCC accounts for 2.8% of all malignancies. In Europe the disease shows its highest prevalence in Hungary, the north of France and Scotland. In India as well as in Brazil, OSCC accounts for 35% of all newly diagnosed cancers in men.
Aetiology
Lifestyle habits and demographic as well as genetic factors influence these geographical variations. The aetiology of HNSCC is well established in most instances -consumption of tobacco in any form and alcohol being the most common risk factors. The effects of lifestyle in the aetiopathogenesis of HNSCC include dietary habits, especially betel quid chewing and low fruit and vegetable consumption. Occasional cases are related to candidosis or syphilis, and exposure to the human papillomavirus (HPV) has been implicated as an aetiopathogenetic agent in oropharyngeal carcinoma, especially in young patients without exposure to tobacco or alcohol.
Diagnosis
HNSCC is usually diagnosed at a late stage, typically because of patient delay, and this has an adverse effect on prognosis. In the US, of the approximately 50,000 new cases of HNSCC diagnosed annually, over 60% are locoregionally advanced (stage III and IV) at diagnosis.
Potentially malignant disorders include:
• erythroplakia (red patch) -the most likely lesion to transform;
• leukoplakia (white patch); and • lichen planus.
Far less common potentially malignant disorders include:
• discoid lupus erythematosus;
• dyskeratosis congenita;
• immunosuppressed states;
• oral submucous fibrosis;
• Paterson-Kelly syndrome (sideropenic dysphagia); and • tertiary syphilis.
Any solitary oral lump, ulcer, white or red lesion persisting for more than three weeks, non-healing tooth extraction socket, numbness or unexplained loose tooth is suspect as oral cancer until proved otherwise (see Figure 1) . Biopsy is mandatory. Second primary neoplasms are common: they are seen in up to 25% of patients with HNSCC over three years.
Management
The goal of treatment is to eradicate disease, preserve or restore form and function, minimise treatment sequelae and prevent any subsequent new primary cancers. Quality of life is crucial.
Factors that influence the choice of initial treatment regimen are related to the characteristics of the primary tumour, to the patient and to the therapeutic team. For the 40% of patients with HNSCC who present with early-stage disease, surgical resection or radiotherapy is recommended as a single treatment modality. : 10.17925/EOH.2009.05.1.25 However, since most patients present with locally advanced disease (LAD), a multidisciplinary approach combining surgery, radiotherapy and chemotherapy is commonly indicated.
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Treatment combinations include:
• surgery followed by adjuvant chemoradiotherapy (CRT) or radiotherapy;
• CRT followed by surgery as a salvage treatment; 
Early-stage Tumours
Outcomes of tumours treated by either surgery or radiotherapy are similar; therefore, treatment sequelae are an important consideration.
Oncologists must also consider the disease site: oral cavity lesions are often treated with surgery followed by radiotherapy or CRT, whereas tumours in the oropharynx, hypopharynx, nasopharynx or larynx are usually treated first with CRT. 
Advanced-stage Tumours
In patients with advanced-stage disease, in many centres in the US, the UK and Canada the current treatment preference is surgical resection with immediate reconstruction followed by post-operative radiation therapy or post-operative concurrent chemo-radiotherapy.
However, in central Europe, and especially in the countries that participate in the European Organisation for Research and Treatment of Cancer (EORTC) and the German, Austrian and Swiss cooperative group on tumours of the maxillofacial region (DOSAK) groups, preoperative chemo-radiotherapy is the standard treatment.
Outcomes
Treatment for HNSCC has permanent effects on organs essential for normal activities such as breathing, speaking, eating and drinking.
Loss of weight and malnutrition due to both cachexia and an inability to take a normal diet are frequent. It is also common for 
Recent Advances
Chemotherapy
Chemotherapeutic agents are increasingly used to enhance the effects of radiotherapy (chemo-radiation), but chemotherapy alone is rarely appropriate for HNSCC. Concomitant chemo-radiation therapy (CCRT) has an improved therapeutic effect for patients with unresectable locoregionally advanced HNSCC, with a distinct survival advantage over either radiotherapy or chemotherapy alone. 
Recent Advances in Oral Oncology
However, the improved overall clinical outcome with CCRT using hyperfractionated radiotherapy comes at the cost of significant treatment-induced morbidity, particularly mucositis, dermatitis, diarrhoea, cardiotoxicity and myelosuppression. Patient selection for these intense treatment regimens must take careful consideration of the patient's overall clinical status. 4 Treatment by experienced physicians with multidisciplinary radiotherapy, medical, surgical, nursing and other supportive care is needed to sustain these patients through such intense treatment protocols. Head and Neck Cancer 
